1257044-40-8

If you are looking for a supplier or manufacturer of ABT-199 (CAS:1257044-40-8), please contact us. For more than 10 years, we have been focusing on custom synthesis and large-scale manufacturing of organic compound products. We can provide high-quality compounds and good service to customers all over the world. Now, we also hope to meet your needs for ABT-199 (CAS:1257044-40-8) and other compounds.

Send Inquiry

Product Description

Name	ABT-199
Synonyms	UNII-N54AIC43PW;Venclyxto (EU Trade name);GDC-0199;CS-1155;RG7601;Venclexta (US Trade name);GDC0199; 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
Molecular Formula	C45H50ClN7O7S
Molecular Weight	868.43900
CAS Number	1257044-40-8
purity	≥98%
Storage conditions	Keep in dark place,Sealed in dry,Store in freezer, under -20°C

Applications：

Venetoclax (INN, trade name Venclexta ven-KLEKS-tuh, previously known as GDC-0199, ABT-199, and RG7601) (CAS:1257044-40-8) is a small molecule oral drug being investigated to treat chronic lymphocytic leukemia (CLL). In 2015, the United States Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to venetoclax for patients with CLL who have relapsed or have been refractory to previous treatment and have the 17p deletion genetic mutation.

Hot Tags: